Ocular Therapeutix (OCUL) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ocular Therapeutix™ Reports Second Quarter 2018 Financial Results and Business Update
August 7, 2018 4:00 PM EDTDEXTENZA® NDA Resubmission Submitted and Accepted by the U.S. Food and Drug Administration
DEXTENZA Given December 28, 2018 Target PDUFA Date
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2018 and provided a business update.
We are encouraged with our progress through the first half of 2018, said Antony Mattessich, President and Chief Executive Officer. The... More
